LivMedCell and University of Pennsylvania Forge Alliance to Revolutionize cancer Treatment
Istanbul, July 8, 2025 – LivMedCell, a leading stem cell therapy center, has announced a collaborative research initiative with the Perelman School of Medicine at the University of Pennsylvania, focused on accelerating advancements in CAR-T cell therapy and personalized oncology. This partnership signifies a major strategic move for livmedcell, extending its expertise beyond its established foundation in regenerative medicine.
Expanding Horizons: A New Era in Immunotherapy
The agreement, finalized in May 2025, represents a commitment to pioneering next-generation cellular therapies. With cancer remaining a leading cause of death globally – accounting for nearly 10 million deaths in 2020 according to the World Health Organization – innovative approaches like CAR-T cell therapy are crucial. This collaboration aims to refine and broaden the submission of these powerful immunotherapies.
LivMedCell, Turkey’s first hospital-based stem cell production center adhering to stringent Good Manufacturing practices (GMP) standards, has been at the forefront of cellular therapies since 2014.The center has provided treatments to thousands of patients originating from Europe, the Middle East, central Asia, and other regions, offering Ministry of Health-approved therapies for a diverse spectrum of chronic and degenerative illnesses.
A Center of Excellence in Regenerative Medicine
LivMedCell’s success is built upon a foundation of rigorous scientific inquiry and a dedication to translating research into tangible clinical benefits. The center operates as a global reference point for regenerative medicine, attracting patients seeking advanced treatment options. This is driven by a team of highly skilled professionals dedicated to pushing the boundaries of cellular therapy.
The dedicated team at livmedcell, pioneering advancements in stem cell therapies.
The center’s leadership includes experts deeply invested in both clinical practice and academic research. Their contributions are reflected in a ample body of published work and recognition within the scientific community.this synergy between research and clinical application ensures that patients benefit from the latest breakthroughs in cellular therapies.
Personalized Treatments Offered by LivMedCell
LivMedCell specializes in tailored stem cell and exosome-based treatments for a range of conditions, including:
- Neurological disorders: such as multiple sclerosis and cerebral palsy, where cellular therapies aim to modulate the immune system and promote nerve regeneration.
- Cardiovascular diseases: including heart failure and peripheral artery disease, utilizing stem cells to repair damaged tissue and improve blood flow.
- Autoimmune diseases: like rheumatoid arthritis and Crohn’s disease, employing cellular therapies to re-establish immune tolerance and reduce inflammation.
- Musculoskeletal conditions: addressing osteoarthritis and sports injuries with the goal of cartilage repair and pain reduction.
- anti-aging and wellness: offering treatments designed to enhance vitality and promote overall health.
This collaboration with the University of Pennsylvania’s perelman School of Medicine promises to unlock new possibilities in personalized cancer treatment, offering hope to patients facing this challenging disease.